65--Manufacture/Distributor Br-Philadelp
Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/09ffe41a0f4e4be1a08aae56e69e11ac/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking a Manufacture/Distributor Br-Philadelp. This service/item is typically used for drugs and biologicals. The notice includes a modification that adds NDC 51407-0426-12 to CLIN 0006 of the contract. For more information, contact DENISE TAUBMAN at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.

    Point(s) of Contact
    DENISE TAUBMAN215-737-8677
    DENISE.TAUBMAN@DLA.MIL
    Files
    Title
    Posted
    signed SPE2D221D0125P00002.pdf
    Lifecycle
    Title
    Type
    65--Manufacture/Distributor Br-Philadelp
    Currently viewing
    Special Notice
    Similar Opportunities
    Lansoprazole Capsules
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting offers for the procurement of Lansoprazole DR 30MG capsules, a pharmaceutical product essential for treating various gastrointestinal conditions. This solicitation outlines the requirements for contractors to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS), emphasizing compliance with Federal Acquisition Regulation (FAR) clauses and ethical business practices. The procurement is critical for maintaining the supply of necessary medications to support military personnel, ensuring adherence to stringent quality and legal standards. Interested contractors should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil, with submissions due by the specified deadline in the solicitation document.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    IBUPROFEN 400MG, 600MG, 800MG TABLETS NATIONAL CONTRACT
    Buyer not available
    Special Notice DEPT OF DEFENSE is seeking IBUPROFEN 400MG, 600MG, 800MG TABLETS. This medication is typically used for pain relief, reducing inflammation, and lowering fever. The notice is from the DEFENSE LOGISTICS AGENCY, DLA TROOP SUPPORT. The primary contact for this procurement is Denise Taubman (denise.taubman@dla.mil, 2157376877) and the secondary contact is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778). The notice includes AMENDMENT 00009 to incorporate telecommunication clauses into the solicitation.
    Dextroamphetamine/Amphetamine National Contract
    Buyer not available
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    MODIFICATION TO CONTRACT
    Buyer not available
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is modifying a contract with DLA TROOP SUPPORT. The modification to the contract is for an undisclosed service or item. The primary contact for this notice is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 2157378677. The details of the modification are not provided in the document.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Buyer not available
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    Fexofenadine HCL Follow On MOD P00002
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents as part of its Pharmacy Uniform Formulary Blanket Purchase Agreement and Additional Discount Program, managed by the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the selection and classification of pharmaceutical agents based on clinical and cost-effectiveness for military beneficiaries. The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review specific drug classes, including Breast Cancer Agents and Targeted Immunomodulatory Biologics, with quotes due by March 20, 2025. Interested vendors should direct inquiries to Tracy Banks at tracy.e.banks2.civ@health.mil or Julianne Canaley at julianne.m.canaley.ctr@health.mil for further details.
    Dextroamphetamine/Amphetamine National Contract
    Buyer not available
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is being modified to change the address for Acetris. This contract is related to the procurement of medical and surgical instruments, equipment, and supplies. The place of performance for this contract is Monmouth Junction, NJ 08852, USA. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 215-737-8677.
    Rabeprazole Sodium DR
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking suppliers for Rabeprazole Sodium DR, a pharmaceutical product essential for various medical treatments. This procurement falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is classified under the PSC code 6505 for Drugs and Biologicals. Rabeprazole Sodium is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers, highlighting its importance in military healthcare. Interested vendors can reach out to Trong Nguyen at Trong.Nguyen@dla.mil or call 215-737-4197 for further details, while Jason Wray is also available at jason.wray@dla.mil or 215-737-0614 for additional inquiries.